Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease

Abstract

Abstract:The aim of this study was to evaluate the variation of some parameters involved in peripheral artery disease progression in diabetic patients with peripheral artery disease after six months of mesoglycan. We enrolled 64 Caucasian, type 2 diabetic patients, with stage IIa peripheral artery disease. They were randomized to mesoglycan (Prisma ® ), 50 mg twice a day, or placebo, for six months. We evaluated: glycemic control, metalloproteinase-2, and -9 (MMP-2, and -9), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion protein-1 (sVCAM-1), interleukin-6 (IL-6), soluble E-selectin (sE-selectin), high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and plasminogen activator inhibitor-1 (PAI-1). We recorded a decrease of MMP-2, MMP-9, sE-selectin, TNF-α, sVCAM-1, and IL-6 compared to baseline, and to placebo in the group treated with mesoglycan. Regarding sICAM-1, and hs-CRP, instead, we recorded a decrease with mesoglycan only compared to baseline. Preliminary results seem to suggest an improvement of pain free walking distance with mesoglycan in 18 patients both compared to baseline and to placebo, even if data should be taken cautiously. Our study showed that supplementation with mesoglycan improved endothelial dysfunction in type 2 diabetic patients with peripheral artery disease. Regarding the preliminary data suggesting also a slight improvement of clinical parameters such as pain free walking distance, more data and a bigger sample of patients are necessary to better verify this aspect.

Mesoglycan connects Syndecan‐4 and VEGFR2 through Annexin A1 and formyl peptide receptors to promote angiogenesis in vitro

“…Numerous studies have explored the use of mesoglycan for treatment of vascular disease and its efficacious anti-thrombotic and fibrinolytic effects [15,25,26,28]. We have established the significant in vitro impact of mesoglycan in skin wound repair.…”

Editorial—Special Issue “Nutraceuticals in Human Health and Disease”

“…The studies conducted by Forney et al [ 6 ] provide evidence that dietary quercetin attenuates adipose tissue expansion and inflammation and alters adipocyte morphology in a tissue-specific manner. Giuseppe et al [ 7 ] describe a randomized placebo-controlled trial to assess the effects of mesoglycan supplementation on endothelial damage and walking distance in diabetic patients with peripheral arterial disease; preliminary data are interesting and open doors for further investigation. Spigoni et al [ 8 ] perform a randomized placebo-controlled trial assessing the effects of a nutraceutical formulation comprising berberine, red yeast rice and chitosan on the non-HDL cholesterol levels.…”